The Stroop test validation in the detection of minimal hepatic encephalopathy in Mexican patients with cirrhosis, preliminary results

Minimal hepatic encephalopathy (MHE) is an important cause of morbi-mortality in patients with cirrhosis; its timely identification has an impact on prognosis; the Stroop Test is a diagnostic tool that can be useful and practical in these patients. Validating this test and calculating the cut-off po...

Full description

Saved in:
Bibliographic Details
Published inAnnals of hepatology Vol. 27; p. 100785
Main Authors Domínguez Cardoso, PF, Pérez Hernández, JL, Higuera de la Tijera, F, Santana Vargas, AD, Montemira Orozco, D, Hinojosa Segura, CI
Format Journal Article
LanguageEnglish
Published Elsevier España, S.L.U 01.12.2022
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Minimal hepatic encephalopathy (MHE) is an important cause of morbi-mortality in patients with cirrhosis; its timely identification has an impact on prognosis; the Stroop Test is a diagnostic tool that can be useful and practical in these patients. Validating this test and calculating the cut-off point for the diagnosis of MHE in our population is important. This study aimed to validate the Stroop Test application and estimate the cut-off point for the diagnosis of MHE in our population. Observational, cross-sectional and prolective study to validate and calculate the cut-off point of the Stroop Test; patients with cirrhosis with and without manifest hepatic encephalopathy will be included, who will undergo the Stroop Test, psychometric score of hepatic encephalopathy (PHES) and the critical flicker frequency test (CFF): ROC curves will be calculated to measure sensitivity, specificity and its cut-off point, healthy subjects will also be included for comparison. The trial was approved by the research ethics committee, and informed consent was obtained. One hundred subjects participated: 50 controls, 33 females (66%) age =43.2±12.1 years; and 50 patients with hepatic cirrhosis: 27 females (54%) age 53.2±8.2 years, of which 54%, 42% and 2% were in Child-Pugh A, B and C, respectively. AUROC was calculated for patients with cirrhosis with and without MHE, AUROC= 0.751 (CI=0.656-.846); cut-off point=183.5 sensitivity (SE)=60% specificity (SP)=74% (Figure 1). For our study sample, we found that the Stroop Test is a good diagnostic tool, taking into account a cut-off point of 183.5 sec. as opposed to 274.9 sec. that the apple application gives us, which is validated in a different population (grade and quality of education). Donation by the volunteer ladies of the Hospital General de México “Dr. Eduardo Liceaga.” The authors declare no potential conflicts of interest.
AbstractList Introduction and Objectives: Minimal hepatic encephalopathy (MHE) is an important cause of morbi-mortality in patients with cirrhosis; its timely identification has an impact on prognosis; the Stroop Test is a diagnostic tool that can be useful and practical in these patients. Validating this test and calculating the cut-off point for the diagnosis of MHE in our population is important. This study aimed to validate the Stroop Test application and estimate the cut-off point for the diagnosis of MHE in our population. Materials and Methods: Observational, cross-sectional and prolective study to validate and calculate the cut-off point of the Stroop Test; patients with cirrhosis with and without manifest hepatic encephalopathy will be included, who will undergo the Stroop Test, psychometric score of hepatic encephalopathy (PHES) and the critical flicker frequency test (CFF): ROC curves will be calculated to measure sensitivity, specificity and its cut-off point, healthy subjects will also be included for comparison. The trial was approved by the research ethics committee, and informed consent was obtained. Results: One hundred subjects participated: 50 controls, 33 females (66%) age =43.2±12.1 years; and 50 patients with hepatic cirrhosis: 27 females (54%) age 53.2±8.2 years, of which 54%, 42% and 2% were in Child-Pugh A, B and C, respectively. AUROC was calculated for patients with cirrhosis with and without MHE, AUROC= 0.751 (CI=0.656-.846); cut-off point=183.5 sensitivity (SE)=60% specificity (SP)=74% (Figure 1). Conclusions: For our study sample, we found that the Stroop Test is a good diagnostic tool, taking into account a cut-off point of 183.5 sec. as opposed to 274.9 sec. that the apple application gives us, which is validated in a different population (grade and quality of education). Funding: Donation by the volunteer ladies of the Hospital General de México “Dr. Eduardo Liceaga.” Declaration of interest: The authors declare no potential conflicts of interest.
Introduction and ObjectivesMinimal hepatic encephalopathy (MHE) is an important cause of morbi-mortality in patients with cirrhosis; its timely identification has an impact on prognosis; the Stroop Test is a diagnostic tool that can be useful and practical in these patients. Validating this test and calculating the cut-off point for the diagnosis of MHE in our population is important. This study aimed to validate the Stroop Test application and estimate the cut-off point for the diagnosis of MHE in our population. Materials and MethodsObservational, cross-sectional and prolective study to validate and calculate the cut-off point of the Stroop Test; patients with cirrhosis with and without manifest hepatic encephalopathy will be included, who will undergo the Stroop Test, psychometric score of hepatic encephalopathy (PHES) and the critical flicker frequency test (CFF): ROC curves will be calculated to measure sensitivity, specificity and its cut-off point, healthy subjects will also be included for comparison. The trial was approved by the research ethics committee, and informed consent was obtained. ResultsOne hundred subjects participated: 50 controls, 33 females (66%) age =43.2±12.1 years; and 50 patients with hepatic cirrhosis: 27 females (54%) age 53.2±8.2 years, of which 54%, 42% and 2% were in Child-Pugh A, B and C, respectively. AUROC was calculated for patients with cirrhosis with and without MHE, AUROC= 0.751 (CI=0.656-.846); cut-off point=183.5 sensitivity (SE)=60% specificity (SP)=74% (Figure 1). ConclusionsFor our study sample, we found that the Stroop Test is a good diagnostic tool, taking into account a cut-off point of 183.5 sec. as opposed to 274.9 sec. that the apple application gives us, which is validated in a different population (grade and quality of education). FundingDonation by the volunteer ladies of the Hospital General de México “Dr. Eduardo Liceaga.” Declaration of interestThe authors declare no potential conflicts of interest.
Minimal hepatic encephalopathy (MHE) is an important cause of morbi-mortality in patients with cirrhosis; its timely identification has an impact on prognosis; the Stroop Test is a diagnostic tool that can be useful and practical in these patients. Validating this test and calculating the cut-off point for the diagnosis of MHE in our population is important. This study aimed to validate the Stroop Test application and estimate the cut-off point for the diagnosis of MHE in our population. Observational, cross-sectional and prolective study to validate and calculate the cut-off point of the Stroop Test; patients with cirrhosis with and without manifest hepatic encephalopathy will be included, who will undergo the Stroop Test, psychometric score of hepatic encephalopathy (PHES) and the critical flicker frequency test (CFF): ROC curves will be calculated to measure sensitivity, specificity and its cut-off point, healthy subjects will also be included for comparison. The trial was approved by the research ethics committee, and informed consent was obtained. One hundred subjects participated: 50 controls, 33 females (66%) age =43.2±12.1 years; and 50 patients with hepatic cirrhosis: 27 females (54%) age 53.2±8.2 years, of which 54%, 42% and 2% were in Child-Pugh A, B and C, respectively. AUROC was calculated for patients with cirrhosis with and without MHE, AUROC= 0.751 (CI=0.656-.846); cut-off point=183.5 sensitivity (SE)=60% specificity (SP)=74% (Figure 1). For our study sample, we found that the Stroop Test is a good diagnostic tool, taking into account a cut-off point of 183.5 sec. as opposed to 274.9 sec. that the apple application gives us, which is validated in a different population (grade and quality of education). Donation by the volunteer ladies of the Hospital General de México “Dr. Eduardo Liceaga.” The authors declare no potential conflicts of interest.
ArticleNumber 100785
Author Santana Vargas, AD
Domínguez Cardoso, PF
Higuera de la Tijera, F
Montemira Orozco, D
Pérez Hernández, JL
Hinojosa Segura, CI
Author_xml – sequence: 1
  givenname: PF
  surname: Domínguez Cardoso
  fullname: Domínguez Cardoso, PF
– sequence: 2
  givenname: JL
  surname: Pérez Hernández
  fullname: Pérez Hernández, JL
– sequence: 3
  givenname: F
  surname: Higuera de la Tijera
  fullname: Higuera de la Tijera, F
– sequence: 4
  givenname: AD
  surname: Santana Vargas
  fullname: Santana Vargas, AD
– sequence: 5
  givenname: D
  surname: Montemira Orozco
  fullname: Montemira Orozco, D
– sequence: 6
  givenname: CI
  surname: Hinojosa Segura
  fullname: Hinojosa Segura, CI
BookMark eNqFUdtu1DAQtVCR2Ba-gBd_ALu1J4ntCIGEKi6VinhoebaMPSEOaRzZaWE_oP_NZBfxgIT6ZHlmzpk555yykylNyNhLKXZSSHU-7Fzqcd6BAKCK0KZ5wjagmnbbtAZO2EYq1WxBGfmMnZYyCFFXjYQNe7jpkV8vOaWZL1gWfu_GGNwS08TjxBfqBlzQHwqp47dxirdu5LSNhjzHyePcuzHRt9-vkM_4K3o38bWP01L4z7j03Mec-1RiecXnjGMkHpf3PGO5G5fynD3t3FjwxZ_3jH398P7m4tP26svHy4t3V1tfSbq_RSN8F6QHrP23UIngVKVJSpAGmrYOBoSRIIRQbQOqU7rWFTQKOmm0AV2dscsjb0husHMmKXlvk4v2UEj5u3WZZI1oVe3aILQCMK7GzrTKCBM06qC1clgTV3Xk8jmVkrH7yyeFXVOxgz2kYtdU7DEVQr05opBk3kfMtvi4mhhiJpfpjvgI_u0_eD9SJN6NP3CPZUh3eSIHrbQFrLDXa-5r7ECuSNBABK__T_Do-t9w48HP
ContentType Journal Article
Copyright 2022
Copyright_xml – notice: 2022
DBID 6I.
AAFTH
AAYXX
CITATION
DOA
DOI 10.1016/j.aohep.2022.100785
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
DatabaseTitleList



Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2659-5982
EndPage 100785
ExternalDocumentID oai_doaj_org_article_64a9d076228a4ef896808d7e7d776ae4
10_1016_j_aohep_2022_100785
S1665268122001272
1_s2_0_S1665268122001272
GroupedDBID ---
.1-
.FO
0R~
1P~
23M
2WC
53G
5GY
77H
AAEDW
AAKDD
AALRI
AAXUO
AAYWO
ABXHO
ACVFH
ADBBV
ADCNI
ADVLN
AENEX
AEUPX
AEVXI
AEXQZ
AFJKZ
AFPUW
AFRHN
AIGII
AITUG
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
APOWU
APXCP
BAWUL
EBD
EBS
EMOBN
F5P
FDB
GROUPED_DOAJ
GX1
M41
OC.
OK1
ON0
P2P
ROL
RSH
SV3
TR2
Z5R
AFCTW
DIK
NCXOZ
0SF
6I.
AAFTH
AAYXX
CITATION
ID FETCH-LOGICAL-c3165-9e80cfd1c2e4cbd30da637043d182594d82081200069526f674732562f1878273
IEDL.DBID DOA
ISSN 1665-2681
IngestDate Wed Aug 27 01:31:58 EDT 2025
Tue Jul 01 00:53:21 EDT 2025
Thu Jul 20 20:10:30 EDT 2023
Sun Feb 23 10:19:46 EST 2025
Tue Aug 26 16:40:56 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License http://creativecommons.org/licenses/by-nc-nd/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3165-9e80cfd1c2e4cbd30da637043d182594d82081200069526f674732562f1878273
OpenAccessLink https://doaj.org/article/64a9d076228a4ef896808d7e7d776ae4
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_64a9d076228a4ef896808d7e7d776ae4
crossref_primary_10_1016_j_aohep_2022_100785
elsevier_sciencedirect_doi_10_1016_j_aohep_2022_100785
elsevier_clinicalkeyesjournals_1_s2_0_S1665268122001272
elsevier_clinicalkey_doi_10_1016_j_aohep_2022_100785
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate December 2022
PublicationDateYYYYMMDD 2022-12-01
PublicationDate_xml – month: 12
  year: 2022
  text: December 2022
PublicationDecade 2020
PublicationTitle Annals of hepatology
PublicationYear 2022
Publisher Elsevier España, S.L.U
Elsevier
Publisher_xml – name: Elsevier España, S.L.U
– name: Elsevier
SSID ssj0043512
Score 2.2979715
Snippet Minimal hepatic encephalopathy (MHE) is an important cause of morbi-mortality in patients with cirrhosis; its timely identification has an impact on prognosis;...
Introduction and ObjectivesMinimal hepatic encephalopathy (MHE) is an important cause of morbi-mortality in patients with cirrhosis; its timely identification...
Introduction and Objectives: Minimal hepatic encephalopathy (MHE) is an important cause of morbi-mortality in patients with cirrhosis; its timely...
SourceID doaj
crossref
elsevier
SourceType Open Website
Index Database
Publisher
StartPage 100785
SubjectTerms Gastroenterology and Hepatology
Title The Stroop test validation in the detection of minimal hepatic encephalopathy in Mexican patients with cirrhosis, preliminary results
URI https://www.clinicalkey.com/#!/content/1-s2.0-S1665268122001272
https://www.clinicalkey.es/playcontent/1-s2.0-S1665268122001272
https://dx.doi.org/10.1016/j.aohep.2022.100785
https://doaj.org/article/64a9d076228a4ef896808d7e7d776ae4
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV07T-QwELYQxYkGwXGI5XFyQUnExnHspAQEQkhLwyHRWdl4rA1aklUSJPgB_G9m7ARtcTqaa6P4kZmx55t4_A1jpwi5Ic3TLHJlLiMqdR9lKo4jcLgjQ5q41NFF4dm9un2Ud0_p01qpL8oJC_TAQXDnSha5xWBbiKyQ4LKcakVYDdpqrQrwTKDo88ZgKuzBiAHCOafyOVxZPPIN-cyuolkAUVUK4XMEqIzymk_y1P1rrmnN3dzssO0BJ_KLML9dtgH1T_ZjNpyE77EP1C9_6BH3rjiixZ6jxVShPhKvao6wjlvofZ5VzRvHiULkBTvEORFHK6cFvVoUy4ZKEr9Tkxm80ZbIB6bVjtMvWl5Wbbtouqo746sWlr4GWPvOMUh_XfbdL_Z4c_3n6jYaSipEZRKjLHLIpqWzcSlAlnObTG2hEo3yshhnpLm0CAjQ5ZMTy1OhnMJoI0FUJFycIZbQyT7brJsaDhiXMpeIHqy2aSkLjR3PtQL0h3MENdpmE3Y2CtWsAnOGGVPKno3XgSEdmKCDCbskwX-9SrTX_gEagxmMwXxnDBMmR7WZ8WYp7oXYUfXvsfXfmkE3rOfOxKYTZmoeyKDInoTwZ_ZiwtRXywGyBCjy3ZCH_-Nzj9gWdRmya47ZZt--wglipH7-2y-HT8CNDBw
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Stroop+test+validation+in+the+detection+of+minimal+hepatic+encephalopathy+in+Mexican+patients+with+cirrhosis%2C+preliminary+results&rft.jtitle=Annals+of+hepatology&rft.au=Dom%C3%ADnguez+Cardoso%2C+PF&rft.au=P%C3%A9rez+Hern%C3%A1ndez%2C+JL&rft.au=Higuera+de+la+Tijera%2C+F&rft.au=Santana+Vargas%2C+AD&rft.date=2022-12-01&rft.pub=Elsevier+Espa%C3%B1a%2C+S.L.U&rft.issn=1665-2681&rft.eissn=2659-5982&rft.volume=27&rft_id=info:doi/10.1016%2Fj.aohep.2022.100785&rft.externalDocID=S1665268122001272
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F16652681%2FS1665268122X00082%2Fcov150h.gif